Abstract Number: 2403 • 2014 ACR/ARHP Annual Meeting
From Early Arthritis Clinic to Remission Clinic: Short-Term Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in DMARD-Induced SDAI-Remission during Drug-Free Follow-up
Background/Purpose The introduction of DAS-driven intensive treatment strategies in early rheumatoid arthritis (RA) has considerably improved outcome and patients’ quality of life. Previous studies have…Abstract Number: 375 • 2014 ACR/ARHP Annual Meeting
Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Background/Purpose: Based on treat-to-target guidelines, the goal of treatment should be remission. Definitions for remission recommended by the ACR/EULAR task force include joint counts and…Abstract Number: 2153 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes in Synovial Fluid Culture ̵ Negative Septic Arthritis
Background/Purpose: Delays in diagnosis and treatment of septic arthritis may be associated with significant morbidity. While many patients with suspected or proven septic arthritis are…Abstract Number: 2037 • 2014 ACR/ARHP Annual Meeting
Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population
Background/Purpose: There is a dearth of information on the incidence rate of myasthenia gravis (MG) in the US and specifically among rheumatoid arthritis (RA) patients. …Abstract Number: 1670 • 2014 ACR/ARHP Annual Meeting
Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus
Background/Purpose To describe the profile of patients included in RELESSER with histologically confirmed lupus nephritis (LN). Methods RELESSER is a multicentre cross-sectional study, with information…Abstract Number: 1524 • 2014 ACR/ARHP Annual Meeting
Rituximab Done! What’s Next in RA?
Background/Purpose The optimal strategy to use biologics after rituximab (RTX) in RA is unknown. We therefore aimed to evaluate the effectiveness of different biologics after…Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…Abstract Number: 1436 • 2014 ACR/ARHP Annual Meeting
Impact of Depression on Clinical and Social Outcomes in Patients with Rheumatoid Arthritis: Comparative Study in Germany and Brazil
Background/Purpose Rheumatoid Arthritis (RA) can be associated with psychological disorders and especially depression. About 13 – 20 % of patients have clinical significant depression. It…
- « Previous Page
- 1
- …
- 8
- 9
- 10